home | intranet | site map | español

[] Screening Platform
  [] Cell cultures
   

Neuron BioPharma uses different cell models to massively search for new chemical entities with hypolipemiant and neuroprotective activity. The company owns cell lines reproducing the most important events of Alzheimer’s disease (sporadic of familiar) as well as other neurological diseases, such as Parkinson or Huntington’s disease.

 

 [] HTS
 
Neuron BioPharma undertakes research programs to discover compounds with neuroprotective and/or hypolipemiant activity form tens of thousands compounds and extracts developed in-house, which come from natural biodiversity. Neuron’s screening systems have been automated and robotized, enabling high-speed analysis and high repeatability.